Thermo Fisher Nears $10B Clario Takeover to Bolster Clinical Trial Tech
Thermo Fisher Scientific is finalizing a $10 billion all-cash acquisition of Clario, a clinical trial data solutions provider, according to sources cited by The Financial Times. The deal WOULD expand Thermo Fisher's capabilities in pharmaceutical and biotech research tools as demand for digitized trial management grows.
An announcement could come as early as Wednesday barring last-minute complications. Clario's software platform is widely adopted for collecting and managing clinical trial data, positioning Thermo Fisher to capitalize on increasing R&D investment across the healthcare sector.